

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**September 2021**

---

**Commission File Number:** 0001723069

---

**Tiziana Life Sciences plc**

(Exact Name of Registrant as Specified in Its Charter)

---

**3<sup>rd</sup> Floor,  
11-12 St James's Square  
London SW1Y 4LB  
United Kingdom**

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

## INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 7, 2021, Tiziana Life Sciences plc (the “Company”) issued a regulatory news service announcement in the United Kingdom announcing a Change of Registered Office (the “RNS Announcement”).

The RNS Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TIZIANA LIFE SCIENCES PLC**

Date: September 7, 2021

By: /s/ Kunwar Shailubhai

Name: Kunwar Shailubhai

Title: Chief Executive Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Regulatory News Service Announcement, dated September 7, 2021</a>

**Tiziana Life Sciences plc  
Change of Registered Office**

London/New York, 7 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("**Old Tiziana**") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces that with immediate effect its registered office has been changed to:

9<sup>th</sup> Floor, 107 Cheapside, London EC2V 6DN.

**For further information please contact:**

Keeren Shah, Finance Director on +44 (0) 207 495 2379 or  
email [info@tizianalifesciences.com](mailto:info@tizianalifesciences.com)